Showing results (1551-1560 of 1,708) with videos related to

Sort By:
Pageof 171
Lancet (London, England)|August 20, 2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trialStephen D Wiviott, Harvey D White, E Magnus Ohman, et al.
Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.
Journal of the American College of Cardiology|September 4, 2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary SyndromeDoron Zahger, Gregory G Schwartz, Weiming Du, et al.
European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
The American Journal of Cardiology|June 13, 2024
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney DiseaseNader Mankerious, Ralph Toelg, Birgit Vogel, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 7, 2022
Public reporting for coronary artery bypass graft surgery: The quest for the optimal scorecardHiba Ghandour, Aaron J Weiss, Mario Gaudino, et al.
Circulation|September 13, 2019
Bleeding and New Cancer Diagnosis in Patients With AtherosclerosisJohn W Eikelboom, Stuart J Connolly, Jacqueline Bosch, et al.
The New England Journal of Medicine|November 17, 2009
Intravenous platelet blockade with cangrelor during PCIDeepak L Bhatt, A Michael Lincoff, C Michael Gibson, et al.
JAMA Cardiology|July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 TrialMarc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.
Pageof 171